FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

doi:10.1016/S1470-2045(15)00122-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

The Lancet. Oncology - 1 Oct 2015

Cremolini Chiara, Loupakis Fotios, Antoniotti Carlotta, Lupi Cristiana, Sensi Elisa, Lonardi Sara, Mezi Silvia, Tomasello Gianluca, Ronzoni Monica, Zaniboni Alberto, Tonini Giuseppe, Carlomagno Chiara, Allegrini Giacomo, Chiara Silvana, D'Amico Mauro, Granetto Cristina, Cazzaniga Marina, Boni Luca, Fontanini Gabriella, Falcone Alfredo

Abstract excerpt

BACKGROUND: In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved progression-free survival of patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. In this updated analysis, we aimed to provide mature results for overall survival-a secondary endpoint-and report treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Camptothecin

Share to Infusions, Intravenous

Share to Irinotecan

Share to Leucovorin

Share to Organoplatinum Compounds

Share to Oxaliplatin

Source

Open in PubMed

Identifiers

PMID: 26338525
DOI: 10.1016/S1470-2045(15)00122-9

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.PMID 26338525Read ↗

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.Semantic proximity Read ↗

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.Semantic proximity Read ↗

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study.Semantic proximity Read ↗

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).Semantic proximity Read ↗

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.Semantic proximity Read ↗

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.Semantic proximity Read ↗

Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer: the IMPROVE-2 trialSemantic proximity Read ↗

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.Semantic proximity Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.